Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Moodys
Mallinckrodt

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Medimmune Oncology Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for MEDIMMUNE ONCOLOGY, and what generic and branded alternatives to MEDIMMUNE ONCOLOGY drugs are available?

MEDIMMUNE ONCOLOGY has one approved drug.



Summary for Medimmune Oncology

Drugs and US Patents for Medimmune Oncology

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 DISCN No No   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Medimmune Oncology

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 4,376,858   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 6,017,922   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 6,017,922   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 4,694,007   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Dow
Medtronic
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.